Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes
Authors
- Oscar C. Marroquin (ORCID: https://orcid.org/0000-0002-0909-0319)
- Floyd Thoma
- Steven E. Reís (ORCID: https://orcid.org/0000-0001-8023-0102)
- Anum Saeed (ORCID: https://orcid.org/0000-0003-1783-678X)
- Suresh Mulukutla (ORCID: https://orcid.org/0000-0001-5060-429X)
- Kevin E. Kip (ORCID: https://orcid.org/0000-0002-6401-0051)
- Agnes Koczo (ORCID: https://orcid.org/0000-0002-8867-0169)
- Lara Lemon
Institutions
- University of Pittsburgh (US)
- UPMC Health System (US)
Publication Details
- Journal
- Annals of Internal Medicine
- Published
- 2025-06-16
- DOI
- https://doi.org/10.7326/annals-24-00775
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18